Clinical Trial

TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

Study acronym: TRITON-PN
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to: * Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality of life, nutritional status, disability, and gait speed * Demonstrate superiority of nucresiran compared to in-study vutrisiran with respect to serum transthyretin (TTR) levels
Protocol Amendment History 5 changes
notable Trial sites expanded: 41 -> 48 locations 2026-08-15
notable Trial sites expanded: 29 -> 41 locations 2026-07-24
notable Trial sites expanded: 16 -> 29 locations 2026-06-13
notable Trial sites expanded: 4 -> 16 locations 2026-05-15
notable Trial sites expanded: 1 -> 4 locations 2026-04-21
Trial Details
NCT Number NCT07223203
Lead Sponsor Alnylam Pharmaceuticals
Conditions Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy, hATTR-PN
Enrollment 125 participants
Start Date 2025-12-12
Primary Completion 2027-12-27 (estimated)
Study Completion 2031-06-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-14